Ortho-Clinical Diagnostics, Inc

George Bashirians

Jian Zheng

Banumathi Sankaran

Edward R Scalice

John W Backus

Deborah Byrne

Sarah Groulx

Sharon Jackson

Heather Lane-Brown

Karen Yang

Methods for determining the presence or amount of a complex comprising a first and second molecular entity are provided, preferably an sFlt-1:PlGF complex. A determination of the presence or amount of the complex can be used in methods for predicting, detecting, monitoring a disease, or guiding therapy in respect to a disease such as vascular, vascular-related disease, cardiac, cardiac-related disease, cancer, cancer-related disease, preeclampsia, and preeclampsia-related disease. Determining sFlt-1:angiogenic factor complex is particularly useful for predicting and detecting preeclampsia in early stages of gestation and in stages of the disease where clinical evaluation may be uninformative.

Determination of sFlt-1:angiogenic factor complex

Disclosed herein are compositions and methods comprising two or more proteins in which at least one of the proteins has been altered to reduce their mutual recognition and binding. Such compositions are useful as reference, calibrators or controls in methods and assays for determining the amount of one or more of the proteins that may be present in a sample of interest or in confirming the presence of one or more of the proteins in the sample. More particularly, it relates to compositions and methods comprising altered placental growth factor-1 (PlGF-1) and soluble fms-like tyrosine kinase (sFlt-1) and methods for determining the amount or confirming the presence of sFlt-1 and/or PlGF-1 in a sample of interest.

Calibrator/control for simultaneous assay of proteins capable of complexing with one another

Reference, calibrator, or control composition of PIGF-1 and sFlt-1

Growing community of inventors

Penfield, NY, United States of America

George Bashirians